Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$133,333.00

Role of Vitamin A metabolism and retinoic acid (RA) signaling in the prevention of Graft-versus- host disease

EF 2013-14

Résumé
Bone marrow transplantation is an attractive treatment option for patients with blood cancer and bone marrow disorders. However, the main complication of this treatment is graft-versus- host disease (GVHD), in which the patient's tissue will be recognized as foreign and attacked by donor white blood cells. GVHD initiation is bolstered by tissue injury and inflammation caused by chemotherapy and radiation given before transplant used to destroy cancer blood cells from the host and also to prevent the rejection of donor bone marrow cells by host immune cells. The gut is a particularly critical target organ for fueling GVHD and such injury causes morbidity and mortality in patients. Our hypothesis is that by reducing inflammatory reaction during intestinal injury may ameliorate GVHD. Recently, our group has demonstrated the critical role of the Vitamin A metabolite, retinoic acid, which is substantially increased during GVHD, in the morbidity and mortality of bone marrow transplantation in a mouse GVHD model that simulates the human disease. By inhibiting retinoic acid signaling in donor white blood cells, intestinal injury and GVHD lethality are markedly decreased. The current proposal aims to identify which form of retinoic acid receptor and vitamin A metabolizing enzymes that need to be targeted to prevent or treat GVHD in rodents and to test new drugs that selectively target these receptors and enzyme function as a prelude to bringing such new therapies into the clinic. The availability and testing of novel drugs targeting this vital pathway has wide applications including solid organ transplants, cancer immunology and autoimmune diseases such as inflammatory bowel disease.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Minnesota, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
300621
Name
Thangavelu Govindarajan
Region
Minnesota
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Role of Vitamin A metabolism and retinoic acid (RA) signaling in the prevention of Graft-versus- host disease
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$133,333
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bioluminescent Imaging; Bone Marrow Transplantation; Flow Cytometry; Graft Versus Host Disease; Graft Versus Leukemia; Histology; Immunohistochemistry; Inflammatory Bowel Disease; Rt-Pcr; Tregulatory Cells; Vitamin A And Rxr Pathways
Abstract
Bone marrow transplantation is an attractive treatment option for patients with blood cancer and bone marrow disorders. However, the main complication of this treatment is graft-versus- host disease (GVHD), in which the patient's tissue will be recognized as foreign and attacked by donor white blood cells. GVHD initiation is bolstered by tissue injury and inflammation caused by chemotherapy and radiation given before transplant used to destroy cancer blood cells from the host and also to prevent the rejection of donor bone marrow cells by host immune cells. The gut is a particularly critical target organ for fueling GVHD and such injury causes morbidity and mortality in patients. Our hypothesis is that by reducing inflammatory reaction during intestinal injury may ameliorate GVHD. Recently, our group has demonstrated the critical role of the Vitamin A metabolite, retinoic acid, which is substantially increased during GVHD, in the morbidity and mortality of bone marrow transplantation in a mouse GVHD model that simulates the human disease. By inhibiting retinoic acid signaling in donor white blood cells, intestinal injury and GVHD lethality are markedly decreased. The current proposal aims to identify which form of retinoic acid receptor and vitamin A metabolizing enzymes that need to be targeted to prevent or treat GVHD in rodents and to test new drugs that selectively target these receptors and enzyme function as a prelude to bringing such new therapies into the clinic. The availability and testing of novel drugs targeting this vital pathway has wide applications including solid organ transplants, cancer immunology and autoimmune diseases such as inflammatory bowel disease.
Competitiondate
201311
Approvedterm2
2 yrs 8 mths
Pinamesdelim
Thangavelu, Govindarajan
Approvedterm
2 ans 8 mois
Cihrcontribution2
~ $133,333~ $0~